NEW YORK, Jan. 8, 2016 /PRNewswire/ -- The article excerpt below from PM360 Magazine, written by Richie Etwaru, chief digital officer, IMS Health (NYSE: IMS), introduces the concept of Orchestrated Customer Engagement to the life sciences industry---a concept that combines the automation of multichannel marketing with the human touch of traditional sales and the power of next-generation technology.
Many life sciences companies are just beginning to formulate or implement multichannel or omnichannel marketing strategies, automating processes that will let them communicate more effectively with healthcare professionals across a number of different channels. Even so, many companies are already thinking about the next big step in the evolution of pharmaceutical sales and marketing: Orchestrated Customer Engagement (OCE).
With OCE, sales, marketing and information technology are closely aligned. The three teams work together to provide customers with relevant and timely information, resources and experiences. The OCE approach to customer engagement is designed to improve the relationship between life sciences companies and their customers, and to increase efficiency across all communication channels and stakeholders while boosting ROI.
To view the entire article as it appears on PM360 Magazine click here:
About IMS Health
IMS Health (NYSE: IMS) is a leading global information and technology services company providing clients in the healthcare industry with end-to-end solutions to measure and improve their performance. Our 7,500 services experts connect configurable SaaS applications to 10+ petabytes of complex healthcare data in the IMS One™ cloud platform, delivering unique insights into diseases, treatments, costs and outcomes. The company's 15,000 employees blend global consistency and local market knowledge across 100 countries to help clients run their operations more efficiently. Customers include pharmaceutical, consumer health and medical device manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and the financial community.
As a global leader in protecting individual patient privacy, IMS Health uses anonymous healthcare data to deliver critical, real-world disease and treatment insights. These insights help biotech and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders to identify unmet treatment needs and understand the effectiveness and value of pharmaceutical products in improving overall health outcomes. Additional information is available at www.imshealth.com.
SOURCE IMS Health